IGF1R and breast carcinoma: Depletion of LMTK3 was shown to enhance the sensitivity of both prostate and breast cancer cells to an IGF1R inhibitor as demonstrated by a reduction in viability when exposed to an IGF1R tyrosine kinase inhibitor.